Video

Dr. Strosberg on Understanding the Current Field of Neuroendocrine Tumors

Author(s):

Jonathan R. Strosberg, MD

In Partnership With:

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, shares his insight on the current field of neuroendocrine tumors (NETs).

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, shares his insight on the current field of neuroendocrine tumors (NETs).

After years of everolimus (Afinitor) and metastin analogs, the field is in a stage of expansion, says Strosberg. Agents such as telotristat ethyl (Xermelo) are signifying that new drugs—although niche—are signaling advancement in the treatment of NETs.

Related Videos
Amma Asare, MD, PhD
Anthony V. D'Amico, MD, PhD
Alexandra Drakaki, MD, PhD
Grzegorz S. Nowakowski, MD
Sagar Lonial, MD, FACP
Joshua Linscott, MD, PhD
Yuan Yuan, MD, PhD
John V. Heymach, MD, PhD, chair, Thoracic/Head and Neck Medical Oncology, and the David Bruton Endowed Chair in Cancer Research, The University of Texas MD Anderson Cancer Center
Komal Jhaveri, MD, FACP
Oana Catalina Rosca, MD
Related Content
Javier Pinilla-Ibarz, MD, PhD, senior member, head, Lymphoma Section, Department of Malignant Hematology, Moffitt Cancer Center
September 9th 2024

Zanubrutinib Associated With Lower Switching Rates vs Other Covalent BTK Inhibitors in CLL/SLL

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

FDA
September 5th 2024

FDA Grants Orphan Drug Designation to Certepetide in Cholangiocarcinoma

Andrew Kuykendall, MD
October 16th 2023

FDA Approval Insights: Momelotinib in Myelofibrosis With Anemia

Weiguo Su, PhD, of HUTCHMED
August 30th 2024

sNDA Withdrawn for Fruquitinib Plus Paclitaxel in Second-Line Gastric Cancer in China

FDA
August 21st 2024

FDA Accepts sBLA for First-Line Nivolumab Plus Ipilimumab in Unresectable HCC